Zegbeh Jallah
Stock Analyst at Capital One
(2.99)
# 1,402
Out of 4,876 analysts
24
Total ratings
36.36%
Success rate
120.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Zegbeh Jallah
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OTLK Outlook Therapeutics | Upgrades: Overweight | $100 | $1.60 | +6,150.00% | 2 | Dec 27, 2023 | |
| EYPT EyePoint Pharmaceuticals | Initiates: Overweight | $44 | $9.64 | +356.43% | 1 | Dec 11, 2023 | |
| KOD Kodiak Sciences | Upgrades: Overweight | n/a | $3.70 | - | 5 | Nov 17, 2023 | |
| IDYA IDEAYA Biosciences | Initiates: Overweight | $29 | $21.37 | +35.70% | 2 | Dec 28, 2022 | |
| RAPT RAPT Therapeutics | Initiates: Overweight | $384 | $8.43 | +4,455.16% | 2 | Sep 21, 2022 | |
| ENTA Enanta Pharmaceuticals | Maintains: Buy | $101 → $70 | $7.50 | +833.33% | 2 | May 12, 2022 | |
| RZLT Rezolute | Initiates: Buy | $21 | $4.35 | +382.76% | 1 | Sep 8, 2021 | |
| ARVN Arvinas | Maintains: Buy | $120 → $135 | $7.54 | +1,690.45% | 2 | Aug 9, 2021 | |
| DARE Daré Bioscience | Maintains: Buy | $108 → $132 | $2.37 | +5,481.40% | 1 | Jun 30, 2021 | |
| OCGN Ocugen | Downgrades: Neutral | $10 → $6 | $0.98 | +509.69% | 2 | Jun 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $55 | $11.41 | +382.03% | 1 | Feb 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $3.05 | - | 1 | Aug 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $0.77 | +938.96% | 1 | May 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $600 | $1.83 | +32,686.89% | 1 | Dec 18, 2019 |
Outlook Therapeutics
Dec 27, 2023
Upgrades: Overweight
Price Target: $100
Current: $1.60
Upside: +6,150.00%
EyePoint Pharmaceuticals
Dec 11, 2023
Initiates: Overweight
Price Target: $44
Current: $9.64
Upside: +356.43%
Kodiak Sciences
Nov 17, 2023
Upgrades: Overweight
Price Target: n/a
Current: $3.70
Upside: -
IDEAYA Biosciences
Dec 28, 2022
Initiates: Overweight
Price Target: $29
Current: $21.37
Upside: +35.70%
RAPT Therapeutics
Sep 21, 2022
Initiates: Overweight
Price Target: $384
Current: $8.43
Upside: +4,455.16%
Enanta Pharmaceuticals
May 12, 2022
Maintains: Buy
Price Target: $101 → $70
Current: $7.50
Upside: +833.33%
Rezolute
Sep 8, 2021
Initiates: Buy
Price Target: $21
Current: $4.35
Upside: +382.76%
Arvinas
Aug 9, 2021
Maintains: Buy
Price Target: $120 → $135
Current: $7.54
Upside: +1,690.45%
Daré Bioscience
Jun 30, 2021
Maintains: Buy
Price Target: $108 → $132
Current: $2.37
Upside: +5,481.40%
Ocugen
Jun 11, 2021
Downgrades: Neutral
Price Target: $10 → $6
Current: $0.98
Upside: +509.69%
Feb 18, 2021
Maintains: Buy
Price Target: $30 → $55
Current: $11.41
Upside: +382.03%
Aug 5, 2020
Initiates: Buy
Price Target: n/a
Current: $3.05
Upside: -
May 13, 2020
Initiates: Buy
Price Target: $8
Current: $0.77
Upside: +938.96%
Dec 18, 2019
Initiates: Buy
Price Target: $600
Current: $1.83
Upside: +32,686.89%